Inhibitors of NO-synthases

The substances of the invention are highly effective low-molecular NO-synthases inhibitors. They can be synthesised easily and inexpensively in high purity via standard methods and exhibit selectivity for the bNOS present in the central nervous system which is involved in neuronal diseases as Alzheimer’s and Parkinson’s disease, multiple sclerosis and migraine. Thus, it is of particular importance that the inhibitors, after oral up-take and subsequent resorption via the intestinal epithelium, are able to cross the blood-brain barrier.

Further Information: PDF

Patent- und Verwertungsagentur für die Wissenschaftlichen Einrichtungen in Schleswig-Holstein GmbH (PVA SH)
Phone: +49 (0)431/8009937

Contact
Dr. Alexandra Baumgartner

Media Contact

info@technologieallianz.de TechnologieAllianz e.V.

All latest news from the category: Technology Offerings

Back to home

Comments (0)

Write a comment

Newest articles

Silicon Carbide Innovation Alliance to drive industrial-scale semiconductor work

Known for its ability to withstand extreme environments and high voltages, silicon carbide (SiC) is a semiconducting material made up of silicon and carbon atoms arranged into crystals that is…

New SPECT/CT technique shows impressive biomarker identification

…offers increased access for prostate cancer patients. A novel SPECT/CT acquisition method can accurately detect radiopharmaceutical biodistribution in a convenient manner for prostate cancer patients, opening the door for more…

How 3D printers can give robots a soft touch

Soft skin coverings and touch sensors have emerged as a promising feature for robots that are both safer and more intuitive for human interaction, but they are expensive and difficult…

Partners & Sponsors